Boston Scientific Q2 net sales rise 7.5% to $5.442 billion; adjusted EPS $0.86
Boston Scientific reported second quarter 2026 net sales of $5.442 billion, up 7.5% on a reported basis, and GAAP EPS of $0.61, up from $0.53 a year earlier. Adjusted EPS of $0.86 was above the company's $0.82 to $0.84 guidance range, and the company now expects full-year 2026 adjusted EPS of $3.28 to $3.32 and third-quarter adjusted EPS of $0.80 to $0.82. Shareholders should note a $76 million litigation-related charge in the quarter and a $1.5 billion investment in MiRus LLC.
Key points
- Net sales of $5.442 billion, up 7.5% reported and 7.0% organic, at the top of the 5.5% to 7.5% reported guidance range
- GAAP net income attributable to common stockholders of $907 million, or $0.61 per share, versus $797 million, or $0.53 per share, a year ago
- Full-year 2026 guidance: reported net sales growth of 5.5% to 6.5% and adjusted EPS of $3.28 to $3.32; third-quarter adjusted EPS of $0.80 to $0.82
- Completed a $2 billion accelerated share repurchase of about 40 million shares and invested $1.5 billion in MiRus LLC for an approximately 34% equity stake
The filing
Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.